![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Judge Limits Attorney Contingency Fees to 15 Percent in $26 Billion Opioid Settlement
Judge Limits Attorney Contingency Fees to 15 Percent in $26 Billion Opioid Settlement
![Judge court](https://www.fdanews.com/ext/resources/test/Drug-Images/Court.gif?t=1628628280&width=430)
August 11, 2021
A federal judge has capped contingency fees at 15 percent for lawyers representing plaintiffs poised to earn large amounts from the pending $26 billion opioid lawsuit settlement by the three largest U.S. drug distributors and Johnson & Johnson (J&J).
Last month, state attorneys general reached the historic settlement agreement with McKesson, Cardinal Health, Amerisource Bergen and J&J, to resolve thousands of lawsuits alleging that the companies fueled the nation’s opioid epidemic.
The cap on attorney contingency fees is meant to ensure that “an appropriate share of the money intended for abatement of the opioid crisis is actually used for that purpose,” wrote Judge Dan Polster of the U.S. District Court for the Northern District of Ohio.
Upcoming Events
-
21Oct